Summary
Twenty patients (aged 26–70 years) with severely impaired renal function received pefloxacin twice daily for 5 days as 12 mg·kg−1 administered as a 1 h i.v. infusion, or 800 mg administered as tablets.
On Day 5 the minimal and maximal plasma concentrations were 5.9 and 11.5 mg·l−1 respectively, after the infusion, and 8.0 and 10.4 mg·l−1, respectively, after oral administration. The steady-state level of the N-desmethyl metabolite ranged from 0.9 (infusion) to 1.2 mg·l−1 (oral route), and that of the N-oxide metabolite ranged from 6.2 (infusion) to 9.0 mg·l−1 (oral route). The minimal concentration of unchanged drug was related to the age of the patients (infusion), but the N-oxide concentration was influenced by the degree of renal impairment (both routes).
The pefloxacin levels were similar to those achieved in healthy subjects, but reduced renal function leads accumulation of its biotransformation products, especially of the N-oxide metabolite which lacks antibacterial activity.
Similar content being viewed by others
References
Hoogkamp-Korstanje JAA (1984) Comparative in vitro activity of five quinolone derivatives and five other antimicrobial agents used in oral therapy. Eur J Clin Microbiol 3: 333–338
King A, Phillips I (1986) The comparative in vitro activity of pefloxacin. J Antimicrob Chemother 17 [Suppl B]: 1–10
Sullam PM, Taüber MG, Hackbarth CJ, Chambers HF, Scott KG, Sande MA (1985) Pefloxacin therapy for experimental endocarditis caused by methicillin-susceptible or methicillin-resistant strains of staphylococcus aureus. Antimicrob Agents Chemother 27: 685–687
Dournon E, Rajagopalan P, Vilde JL, Pocidalo JJ (1986) Efficacy of pefloxacin in comparison with erythromycin in the treatment of experimental guinea pig legionellosis. J Antimicrob Chemother 17 [Suppl B]: 41–48
Nord CE, Edlund C, Lahnborg G (1980) The efficacy of pefloxacin in comparison to gentamicin in the treatment of experimentally induced peritonitis in rats. J Antimicrob Chemother 17 [Suppl B]: 59–63
Wolff M, Pangon B, Regnier B, Rouveix E, Bauchet J, Vachon F (1986) Traitement des septicémies et endocardites par la péfloxacine. Presse Med 15: 471–474
Lauwers S, Vincken W, Naessens A, Pierard D (1986) Efficacy and safety of pefloxacin in the treatment of severe infections in patients hospitalized in intensive care units. J Antimicrob Chemother 17 [Suppl B]: 111–115
Frydman AM, Le Roux Y, Lefebvre MA, Djebbar F, Fourtillan JB, Gaillot J (1986) Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers. J Antimicrob Chemother 17 [Suppl B]: 65–79
Danan G, Montay G, Cunci R, Erlinger S (1985) Pefloxacin kinetics in cirrhosis. Clin Pharmacol Ther 38: 439–442
Montay G, Jacquot C, Bariety J, Cunci R (1985) Pharmacokinetics of pefloxacin in renal insufficiency. Eur J Clin Pharmacol 29: 345–349
Montay G, Goueffon Y, Roquet F (1984) Absorption, distribution, metabolic fate and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys and humans. Antimicrob Agents Chemother 25: 463–472
Montay G, Tassel JP (1985) Improved high-performance liquid chromatographic determination of pefloxacin and its main active metabolite in human plasma or tissue. J Chromatogr 339: 214–218
Arrigo G, Cavaliere G, D'Amico G, Passarella E, Brocalli G (1985) Pharmacokinetics of norfloxacin in chronic renal failure. Int J Clin Pharmacol Ther Toxicol 23: 491–496
Dow J, Chazal J, Frydman AM, Janny P, Woehrle R, Djebbar F, Gaillot J (1986) Transfer kinetics of pefloxacin into cerebro-spinal fluid after one hour i.v. infusion of 400 mg in man. J Antimicrob Chemother 17 [Suppl B]: 81–87
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jungers, P., Ganeval, D., Hannedouche, T. et al. Steady-state levels of pefloxacin and its metabolites in patients with severe renal impairment. Eur J Clin Pharmacol 33, 463–467 (1987). https://doi.org/10.1007/BF00544236
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00544236